Startseite › Akute myeloische Leukämie › Texas › Dallas
Klinische Studien zu Akute myeloische Leukämie in Dallas, TX
21 Studien zu Akute myeloische Leukämie suchen Teilnehmer an Standorten in und um Dallas (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Teilnehmer gesuchtPhase 3
- Baylor University Medical Center, Dallas
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Teilnehmer gesuchtPhase 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Teilnehmer gesuchtPhase 1
- Children's Medical Center Dallas /ID# 275930, Dallas
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Teilnehmer gesuchtPhase 1/2
- Baylor Scott & White Health, Dallas
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Teilnehmer gesuchtPhase 3
- US-Dallas TX-SOUTHWESTERN, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Teilnehmer gesuchtPhase 1/2
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Teilnehmer gesuchtPhase 3
- Harold C. Simmons Comprehensive Cancer Center, Dallas
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Teilnehmer gesuchtPhase 3
- Texas Oncology-Presbyterian Cancer Center, Dallas
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- UT Southwestern/Simmons Cancer Center, Dallas
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Teilnehmer gesuchtPhase 3
- Baylor Charles A. Sammons Cancer Center, Dallas
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Teilnehmer gesuchtBeobachtungsstudie
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Teilnehmer gesuchtPhase 2
- UT Southwestern Medical Center at Dallas, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- Baylor University Medical Center, Dallas
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Teilnehmer gesuchtPhase 1
- UT Southwestern Medical Center, Dallas
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Teilnehmer gesuchtPhase 2/3
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Teilnehmer gesuchtPhase 1
- UT Southwestern - Simmons Cancer Center, Dallas
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern Medical Center, Dallas
Akute myeloische Leukämie-Studien in anderen Städten
- Houston, TX85 Studien
- New York City, NY51 Studien
- Boston, MA44 Studien
- Baldwin Park, CA40 Studien
- Seattle, WA40 Studien
- Columbus, OH35 Studien
- Philadelphia, PA34 Studien
- Durham, NC33 Studien
- Atlanta, GA30 Studien
- Tampa, FL29 Studien
- Chicago, IL26 Studien
- Portland, OR25 Studien
Weitere Studien in Dallas
- Brustkrebs55 Studien
- Nichtkleinzelliges Lungenkarzinom52 Studien
- Metastasierender Krebs42 Studien
- Herzinsuffizienz42 Studien
- Krebs (alle Arten)37 Studien
- Prostatakrebs36 Studien
- Kolorektales Karzinom33 Studien
- Adipositas30 Studien
- Eierstockkrebs28 Studien
- Blasenkrebs27 Studien
- Lungenkrebs27 Studien
- Endometriumkarzinom24 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.